12/02/2025
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) & TP53 mutant AML Patients
Shattuck Labs, Inc. announced updated interim data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.